Non-Hodgkin's B-cell Lymphoma

Update on Status of Trials Announced

Published in Cancer Weekly, September 15th, 1997

Techniclone Corp., Tustin, California, announced that Alpha Therapeutic Corp. (Alpha) has scheduled a meeting with the U.S. Food and Drug Administration (FDA) for October 28, 1997, to discuss expansion of the Phase III clinical trial of I-131 LYM-1 (OncolymTM) and to discuss certain requested protocol changes for patient selection and treatment during the remainder of the expanded Phase III trial.

Alpha completed the patient imaging portion of the Phase III trial and submitted the final imaging and dosimetry data reports to the FDA in August 1997. The Phase III trial of I-131 LYM-1 (OncolymTM) is being sponsored by Alpha and involves the treatment of patients with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-09-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry